Codexis, Inc. (CDXS) News
Filter CDXS News Items
CDXS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDXS News Highlights
- CDXS's 30 day story count now stands at 6.
- Over the past 16 days, the trend for CDXS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC, RNA and ECO are the most mentioned tickers in articles about CDXS.
Latest CDXS News From Around the Web
Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insu |
Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The CompanyCodexis, Inc. ( NASDAQ:CDXS ) shares have continued their recent momentum with a 41% gain in the last month alone... |
Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?Codexis, Inc. ( NASDAQ:CDXS ), might not be a large cap stock, but it received a lot of attention from a substantial... |
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA PolymeraseDeal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymesREDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global excl |
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ PlatformMilestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the preparative-scale manufacture o |
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics ManufacturingREDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023, to discuss the growth of RNA interference (RNAi) therapeutics as a modality, the manufacturing landscape and the potential role for the Company’s Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform to enable commercial-scale production of RNAi therapeutics. KOL participants included John Mar |
Codexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 92% Above Its Share PriceKey Insights The projected fair value for Codexis is US$4.65 based on 2 Stage Free Cash Flow to Equity Codexis is... |
3 Synthetic Biology Stocks Likely to Mint New MillionairesSynthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks. |
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference (RNAi) therapeutics manufacturing landscape on Friday, December 8, 2023, at 10:00 am ET. The event will feature John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuti |
Codexis to Participate in 35th Annual Piper Sandler Healthcare ConferenceREDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York. Management will participate in a fireside chat on Tuesday, November 28, 2023, at 9:30 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A re |